ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Biodesix Inc

Biodesix Inc (BDSX)

1.77
-0.01
(-0.56%)
Closed July 20 4:00PM
1.76
-0.01
(-0.56%)
After Hours: 7:59PM

Calls

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.500.000.750.000.000.000.00 %00-
5.000.001.900.000.000.000.00 %00-

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Puts

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.500.402.050.001.2250.000.00 %00-
5.002.953.700.003.3250.000.00 %00-

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SERVServe Robotics Inc
$ 7.51
(185.55%)
266.26M
AUGXAugmedix Inc
$ 2.27
(147.71%)
24.14M
XCURExicure Inc
$ 0.5351
(76.02%)
14.02M
PSNLPersonalis Inc
$ 3.83
(56.33%)
22.8M
MDBHMDB Capital Holdings LLC
$ 10.675
(37.21%)
126.45k
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
119.98M
HYZNHyzon Motors Inc
$ 0.149
(-47.54%)
23.37M
MEDSTRxADE Health Inc
$ 14.92
(-33.45%)
204.34k
SILOSilo Pharma Inc
$ 2.50
(-27.95%)
11.12M
KITTNauticus Robotics Inc
$ 0.0935
(-27.46%)
26.52M
SERVServe Robotics Inc
$ 7.51
(185.55%)
262.73M
NVDANVIDIA Corporation
$ 117.93
(-2.61%)
206.41M
SXTP60 Degrees Pharmaceuticals Inc
$ 0.2602
(5.77%)
202.14M
SQQQProShares UltraPro Short QQQ
$ 8.46
(2.79%)
184.21M
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
119.98M

BDSX Discussion

View Posts
AJ Freely AJ Freely 1 year ago
$BDSX - Up 12%/ Current Price $1.34.
Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules
๐Ÿ‘๏ธ0
1hot toddy 1hot toddy 2 years ago
WOOOOOOW 130K SHARES BUY NOW 2.6 MIL SHARE BUY $

3 MILLION $ BUY $$$$$$$$$$$$$$$$$$$$$$
๐Ÿ‘๏ธ0
Leg58 Leg58 2 years ago
Lots if potential but will public offering dilute price?
๐Ÿ‘๏ธ0
Leg58 Leg58 2 years ago
Lots if potential but will public offering dilute price?
๐Ÿ‘๏ธ0
subslover subslover 2 years ago
Earnings look good.
๐Ÿ‘๏ธ0
subslover subslover 2 years ago
Earnings look good.
๐Ÿ‘๏ธ0
MiamiGent MiamiGent 2 years ago
BDSX Has news this morning!

The contract covers the companyโ€™s entire lung diagnostic portfolio: Nodify XL2®, Nodify CDT®, VeriStrat®, GeneStrat® ddPCR, and GeneStrat NGSโ„ข testing.

https://investors.biodesix.com/news-releases/news-release-details/biodesix-awarded-us-federal-supply-schedule-contract-its

https://stockcharts.com/h-sc/ui?s=BDSX
๐Ÿ‘๏ธ0
carusso carusso 2 years ago
Not so much...
๐Ÿ‘๏ธ0
crudeoil24 crudeoil24 2 years ago
LET'S GO BDSX !!!!!
๐Ÿ‘๏ธ0
crudeoil24 crudeoil24 2 years ago
Biodesix to Participate in Two Upcoming Investor Conferences in September
6:00 am ET September 6, 2022 (BusinessWire) Print
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will participate in two upcoming investor conferences:

Morgan Stanley 20th Annual Global Healthcare Conference Date: Tuesday, September 13, 2022 at 9:10 a.m. ET Format: Fireside Chat and 1x1 meetings Location: Sheraton Hotel, New York, NY Details: The fireside chat will be webcast live and available for replay under "News & Events" in the Investors section of the Company's website at www.biodesix.com.

H.C. Wainwright 24th Annual Global Investment Conference Dates: September 12-14, 2022 Format: 1x1 meetings Location: Lotte New York Palace Hotel, New York, NY
๐Ÿ‘๏ธ0
crudeoil24 crudeoil24 2 years ago
Biodesix, Inc. is a United States-based company engaged in developing and commercializing blood-based diagnostic tests for oncology. The Companyโ€™s product Biodesix Lung Reflex integrates genomic and proteomic blood-based results to reveal both sides of lung cancer. Its GeneStrat test offers blood-based mutation results within 72 hours for patients with non-small cell lung cancer (NSCLC). Its VeriStrat testing provides blood-based predictive and prognostic proteomic information with (NSCLC) who test negative for estimated glomerular filtration rate (EGFR) mutations (EGFR wild-type) or whose EGFR mutation status is unknown.
๐Ÿ‘๏ธ0
Leg58 Leg58 2 years ago
US based company is quietly trending up. IMHO.
GLTA
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock